In his interview at ESMO 2018, Dr Ian Chau discusses the RAINFALL trial, a randomised, double-blind, placebo-controlled phase III trial to assess the combination of cisplatin plus capecitabine/5-fluorouracil chemotherapy with ramucirumab (a monoclonal antibody against VEGFR2) in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. A total of 645 patients were randomised to cisplatin plus capecitabine/5-fluorouracil chemotherapy with ramucirumab, or cisplatin plus capecitabine/5-fluorouracil chemotherapy with placebo. Dr Chau explains the results of the trial and their implications, and provides an insight into the quality-of-life outcomes and how these are translated into clinical practice. He also discusses the limitations of the trial, which are largely geographical, based on the demographic of the disease and difference in standard of care between different countries. Finally, he suggests how the results of this trial, and other recent trials, may shape future of clinical trials with ramucirumab and the treatment landscape.
1. Could you tell us a little about the rationale and design of the RAINFALL study? (0:11)
2. What were the main efficacy and safety findings of the study? (1:51)
3. What were the quality of life findings from the study? (2:44)
4. What were the limitations of this study (7:36)?
5. What are the next steps in the clinical development of ramucirumab in the second-line treatment of gastric and gastroesophageal adenocarcinoma? (8:55)
Speaker disclosures: Ian Chau has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Gastrointestinal Oncology
Jared Weiss, ESMO 2021: The Efficacy and Safety Findings of the KRYSTAL-1 Study
touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation. Questions 1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? […]
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!